This breast cancer thought-leader discussion, with associated slide deck and eNewsflash, provides participants with valuable updates and expert perspectives on exciting new data in hormone receptor (HR)-positive breast cancer released at the 2018 Annual Breast Cancer Meeting in San Antonio.
Dec 11, 2018
Dec 11, 2019
Robert Coleman, MD, FRCP, FRCPE,
Medical Director, prIME Oncology,
University of Sheffield
Weston Park Hospital, Sheffield, United Kingdom
- Yen-Shen Lu, MD, National Taiwan University, Taipei, Taiwan
- Debu Tripathy, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
Abstract P6-18-07: Ribociclib + endocrine therapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer presenting with visceral metastases: Subgroup analysis of phase III MONALEESA trials
Abstract P6-18-14: Patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2, -3, and -7 trials
Abstract P4-01-20: Circulating tumor DNA as a predictive biomarker of response to palbociclib-fulvestrant in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer
Abstract GS3-02: PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib
Abstract P3-10-08: Markers of response to CDK4 & 6 inhibition from neoMONARCH: A phase II neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive, HER2 negative breast cancer
Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial
Robert Coleman, MD, FRCP, FRCPEMedical Director, prIME Oncology
University of Sheffield
Weston Park Hospital
Sheffield, United Kingdom
Yen-Shen Lu, MDNational Taiwan University
Debu Tripathy, MDThe University of Texas
MD Anderson Cancer Center
Houston, Texas, United States
This educational activity is specifically designed for oncologists and other healthcare professionals involved in the management of patients with HR-positive breast cancer.
After successful completion of this educational activity, participants should be able to:
- Evaluate emerging clinical trial data investigating the safety and efficacy of combination approaches for HR-positive, HER2-negative breast cancer
- Select appropriate treatment approaches for HR-positive, HER2-negative breast cancer and identify the optimal sequence of treatment options
This educational activity is supported by a grant from Novartis Oncology.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Lu has disclosed board membership with Novartis. He also received consulting fees from Boehringer Ingelheim and Novartis. He disclosed honoraria for promotional speaker’s bureaus from Merck, Novartis, Pfizer, and Roche. Furthermore, he disclosed independent contracting for Merck, Novartis, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Tripathy has disclosed that he has received consulting fees from Novartis, Pfizer, and Polyphor. He also disclosed independent contracting for Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Robert Coleman, MD, FRCP, FRCPE – chair of Inbiomotion Scientific and Clinical Advisory Board; consulting fees for advising on clinical trial protocol development from Amgen, Astellas, and Boehringer Ingelheim; intellectual property rights as co-inventor and patent holder of biomarker under development by Inbiomotion; independent medical education lectures at symposia supported by Amgen, Eisai, and Genomic Health; and travel expenses from Amgen for presentation of clinical trial data at ASCO 2018 conference
- Amy Furedy, RN, OCN – no relevant financial relationships
- Heather Tomlinson, ELS – no relevant financial relationships
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.